PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 20, 2026Cancer Immunology Research0 citations

Abstract C071: Obesity impairs anti-tumor responses to breast cancer vaccination

View Full Paper
AJAbigail A. JolleyECErika J. CrosbyGDGabrielle P. Dailey

Key Points

  • The aim is to understand how obesity affects the efficacy of cancer vaccinations in breast cancer treatment.
  • Used a pre-clinical model of spontaneous breast cancer driven by HER2 isoform.
  • Investigated the impact of obesity on therapeutic vaccination after tumor detection.
  • Compared immune responses between obese mice on a high-fat diet and lean mice on a low-fat diet.
  • Therapeutic vaccination protected 100% of lean mice from tumor development, while only 30% of obese mice were protected.
  • Obese mice showed higher serum leptin levels and longer times to tumor formation.
  • Initial findings indicate that obesity skews both local and systemic immune memory.

Abstract

Abstract While advances in immunotherapy have improved treatment of breast cancer, many patients do not respond to current immunotherapies, there is not a reliable predictor of immunotherapy efficacy, and responders may develop resistance to immunotherapies. Additionally, obese breast cancer patients have advanced disease at diagnosis, differential responses to therapies, and worsened prognoses. As obesity has become a worldwide epidemic, understanding how obese patients develop breast cancer and respond to therapeutics is of critical importance. One emerging field of treatment in immune oncology is the use of cancer vaccines that stimulate the patient’s immune system against an antigen expressed on tumors. Obesity within the context of infectious diseases has been shown to cause diminished vaccine-induced immune responses. However, there is a significant gap in our understanding of how obesity impacts vaccination efficacy in the context of cancer. Our group has previously published the use of a pre-clinical therapeutic vaccine targeting HER2 in combination with a checkpoint inhibitor. Using this therapeutic, we hypothesized that obesity would reduce the efficacy of therapeutic vaccination. We used our published model of spontaneous breast cancer driven by expression of a HER2 isoform to investigate the impact of obesity on therapeutic vaccination. On a high fat diet, mice gain significantly more weight and have significantly higher serum leptin levels than their low fat diet counterparts. Obese mice also have a longer time to both tumor formation and tumor endpoint. Importantly, therapeutic vaccination early after tumor detection completely protects lean mice from tumor development, while only 30% of obese mice are protected from tumor development. Early analysis suggests obesity skews immune memory both locally and systemically. It is critical that we understand the anti-tumor response of obese patients to immunotherapies to effectively treat patients. Citation Format: Abigail Jolley, Erika Crosby, Gabrielle Dailey, Jessica Finkler, Christopher Rabiola. Obesity impairs anti-tumor responses to breast cancer vaccination abstract. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr C071.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Jolley et al. (2026) studied this question.

synapsesocial.com/papers/6997fa49ad1d9b11b34536bdhttps://doi.org/10.1158/2326-6074.io2026-c071
Ask AI
Helpful
Bookmark
Share
View Full Paper